I get the sense that we are getting closer to a partnership or licensing of an indication with all of the new hires of heavyweights.

What does the board think? Do we have to have new data from the studies and trials outstanding or is there enough for a deal on an indication? And what would be the potential differences between a partnership and a licensing deal?

Just wondering and open to all opinions on this.

Thanks, Ramjet